Matthew T Houdek1, Peter S Rose1, Mario Hevesi1, Joseph H Schwab2, Anthony M Griffin3, John H Healey4, Ivy A Petersen5, Thomas F DeLaney6, Peter W Chung7, Michael J Yaszemski1, Jay S Wunder3, Francis J Hornicek8, Patrick J Boland4, Franklin H Sim1, Peter C Ferguson3. 1. Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota. 2. Department of Orthopaedic Surgery, Orthopaedic Oncology Service, Massachusetts General Hospital, Boston, Massachusetts. 3. Division of Orthopaedic Surgery, Department of Surgery, University Musculoskeletal Oncology Unit Mount Sinai Hospital, University of Toronto, Toronto, Canada. 4. Orthopaedic Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill College of Medicine, Cornell University, New York, New York. 5. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. 6. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 7. Department of Radiation Oncology, Princess Margaret Cancer Center, Toronto, Canada. 8. Department of Orthopedic Surgery, University of California Los Angeles, Los Angeles, California.
Abstract
BACKGROUND: We reviewed the disease control and complications of the treatment of sacrococcygeal chordoma from four tertiary cancer centers with emphasis on the effects of radiotherapy in surgically treated patients. METHODS: A total of 193 patients with primary sacrococcygeal chordoma from 1990 to 2015 were reviewed. There were 124 males, with a mean age of 59 ± 15 years and a mean follow-up of 7 ± 4 years. Eighty-nine patients received radiotherapy with a mean total dose of 61.8 ± 10.9 Gy. RESULTS: The 10-year disease-free and disease-specific survival was 58% and 72%, respectively. Radiation was not associated with local recurrence (hazard ratio [HR], 1.13; 95% confidence interval [CI], 0.59-2.17; P = 0.71), metastases (HR, 0.93; 95% CI, 0.45-1.91; P = 0.85) or disease-specific survival (HR, 0.96; 95% CI, 0.46-2.00; P = 0.91). Higher doses (≥70 Gy; HR, 0.52; 95% CI, 0.20-1.32; P = 0.17) may be associated with reduced local recurrence. Radiotherapy was associated with wound complications (HR, 2.76; 95% CI, 1.64-4.82;, P < 0.001) and sacral stress fractures (HR, 4.73; 95% CI, 1.88-14.38; P < 0.001). CONCLUSIONS: In this multicenter review, radiotherapy was not associated with tumor outcome but associated with complications. The routine use of radiotherapy with en-bloc resection of sacrococcygeal chordomas should be reconsidered in favor of a selective, individualized approach with a radiation dose of ≥70 Gy.
BACKGROUND: We reviewed the disease control and complications of the treatment of sacrococcygeal chordoma from four tertiary cancer centers with emphasis on the effects of radiotherapy in surgically treated patients. METHODS: A total of 193 patients with primary sacrococcygeal chordoma from 1990 to 2015 were reviewed. There were 124 males, with a mean age of 59 ± 15 years and a mean follow-up of 7 ± 4 years. Eighty-nine patients received radiotherapy with a mean total dose of 61.8 ± 10.9 Gy. RESULTS: The 10-year disease-free and disease-specific survival was 58% and 72%, respectively. Radiation was not associated with local recurrence (hazard ratio [HR], 1.13; 95% confidence interval [CI], 0.59-2.17; P = 0.71), metastases (HR, 0.93; 95% CI, 0.45-1.91; P = 0.85) or disease-specific survival (HR, 0.96; 95% CI, 0.46-2.00; P = 0.91). Higher doses (≥70 Gy; HR, 0.52; 95% CI, 0.20-1.32; P = 0.17) may be associated with reduced local recurrence. Radiotherapy was associated with wound complications (HR, 2.76; 95% CI, 1.64-4.82;, P < 0.001) and sacral stress fractures (HR, 4.73; 95% CI, 1.88-14.38; P < 0.001). CONCLUSIONS: In this multicenter review, radiotherapy was not associated with tumor outcome but associated with complications. The routine use of radiotherapy with en-bloc resection of sacrococcygeal chordomas should be reconsidered in favor of a selective, individualized approach with a radiation dose of ≥70 Gy.
Authors: Larry T Todd; Michael J Yaszemski; Bradford L Currier; Bruno Fuchs; Choll W Kim; Franklin H Sim Journal: Clin Orthop Relat Res Date: 2002-04 Impact factor: 4.176
Authors: Brian O'Sullivan; Aileen M Davis; Robert Turcotte; Robert Bell; Charles Catton; Pierre Chabot; Jay Wunder; Rita Kandel; Karen Goddard; Anna Sadura; Joseph Pater; Benny Zee Journal: Lancet Date: 2002-06-29 Impact factor: 79.321
Authors: Matthew R Claxton; Matthew B Shirley; Joshua D Johnson; Kevin I Perry; Peter S Rose; Matthew T Houdek Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155
Authors: Yagiz U Yolcu; Jad Zreik; Waseem Wahood; Atiq Ur Rehman Bhatti; Mohamad Bydon; Matthew T Houdek; Peter S Rose; Anita Mahajan; Ivy A Petersen; Michael G Haddock; Safia K Ahmed; Nadia N Laack; Krishan Jethwa; Elizabeth B Jeans; Reiko Imai; Shigeru Yamada; Robert L Foote Journal: JAMA Netw Open Date: 2022-01-04
Authors: Matthew T Houdek; Mario Hevesi; Joseph H Schwab; Michael J Yaszemski; Anthony M Griffin; John H Healey; Peter C Ferguson; Francis J Hornicek; Patrick J Boland; Franklin H Sim; Peter S Rose; Jay S Wunder Journal: J Surg Oncol Date: 2019-11-22 Impact factor: 2.885